NGL Fine-Chem Limited (NGLFINE.BO)
INR 2040.15
(2.62%)
INR 2040.15
(2.62%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 416.27 Million INR | 75.89% |
| 2022 | 236.65 Million INR | -59.07% |
| 2021 | 578.26 Million INR | -24.24% |
| 2020 | 763.25 Million INR | 583.99% |
| 2019 | 111.58 Million INR | -58.42% |
| 2018 | 268.39 Million INR | 88.01% |
| 2017 | 142.75 Million INR | -23.66% |
| 2016 | 187 Million INR | -2.78% |
| 2015 | 192.35 Million INR | 57.7% |
| 2014 | 121.97 Million INR | 39.94% |
| 2013 | 87.16 Million INR | 54.55% |
| 2012 | 56.4 Million INR | 127.62% |
| 2011 | 24.77 Million INR | -43.82% |
| 2010 | 44.1 Million INR | 4.64% |
| 2009 | 42.14 Million INR | 17.92% |
| 2008 | 35.74 Million INR | 549.88% |
| 2007 | 5.5 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 63.45 Million INR | -50.81% |
| 2023 Q4 | 129.01 Million INR | -11.66% |
| 2023 FY | 416.27 Million INR | 75.89% |
| 2023 Q1 | 70.05 Million INR | -31.95% |
| 2023 Q2 | 110.79 Million INR | 58.16% |
| 2023 Q3 | 146.04 Million INR | 31.81% |
| 2022 Q1 | -21.02 Million INR | -129.67% |
| 2022 Q3 | 85.82 Million INR | 45.37% |
| 2022 Q2 | 59.03 Million INR | 380.8% |
| 2022 Q4 | 102.94 Million INR | 19.95% |
| 2022 FY | 236.65 Million INR | -59.07% |
| 2021 Q3 | 100.69 Million INR | -32.71% |
| 2021 Q4 | 70.86 Million INR | -29.62% |
| 2021 Q1 | 213.88 Million INR | 14.32% |
| 2021 FY | 578.26 Million INR | -24.24% |
| 2021 Q2 | 149.64 Million INR | -30.03% |
| 2020 FY | 763.25 Million INR | 583.99% |
| 2020 Q2 | 211.16 Million INR | 56.03% |
| 2020 Q4 | 187.08 Million INR | -21.39% |
| 2020 Q3 | 237.99 Million INR | 12.71% |
| 2020 Q1 | 135.33 Million INR | 324.67% |
| 2019 FY | 111.58 Million INR | -58.42% |
| 2019 Q4 | 31.86 Million INR | 35.47% |
| 2019 Q1 | 79.35 Million INR | -40.48% |
| 2019 Q3 | 23.52 Million INR | -30.61% |
| 2019 Q2 | 33.9 Million INR | -57.28% |
| 2018 Q4 | 133.31 Million INR | 105.58% |
| 2018 FY | 268.39 Million INR | 88.01% |
| 2018 Q2 | 72.41 Million INR | 21.76% |
| 2018 Q1 | 59.47 Million INR | 15.52% |
| 2018 Q3 | 64.84 Million INR | -10.45% |
| 2017 Q2 | 52.88 Million INR | 132.03% |
| 2017 Q4 | 51.48 Million INR | -19.11% |
| 2017 FY | 142.75 Million INR | -23.66% |
| 2017 Q3 | 63.64 Million INR | 20.34% |
| 2017 Q1 | 22.79 Million INR | -58.78% |
| 2016 Q1 | 64.91 Million INR | 11.97% |
| 2016 FY | 187 Million INR | -2.78% |
| 2016 Q3 | 65.7 Million INR | 41.6% |
| 2016 Q4 | 55.29 Million INR | -15.84% |
| 2016 Q2 | 46.39 Million INR | -28.52% |
| 2015 Q1 | 46.65 Million INR | -0.98% |
| 2015 Q3 | 42.57 Million INR | -3.26% |
| 2015 Q4 | 57.97 Million INR | 36.15% |
| 2015 FY | 192.35 Million INR | 57.7% |
| 2015 Q2 | 44.01 Million INR | -5.67% |
| 2014 Q2 | 37.27 Million INR | 23.48% |
| 2014 Q4 | 47.12 Million INR | 493.0% |
| 2014 FY | 121.97 Million INR | 39.94% |
| 2014 Q1 | 30.18 Million INR | 109.63% |
| 2014 Q3 | 7.94 Million INR | -78.68% |
| 2013 Q2 | 26.41 Million INR | -6.03% |
| 2013 Q4 | 14.39 Million INR | 1.75% |
| 2013 FY | 87.16 Million INR | 54.55% |
| 2013 Q3 | 14.15 Million INR | -46.43% |
| 2013 Q1 | 28.11 Million INR | 52.76% |
| 2012 Q1 | 17.7 Million INR | 99.75% |
| 2012 FY | 56.4 Million INR | 127.62% |
| 2012 Q4 | 18.4 Million INR | 55.63% |
| 2012 Q3 | 11.82 Million INR | 50.62% |
| 2012 Q2 | 7.85 Million INR | -55.67% |
| 2011 Q3 | 4.95 Million INR | 0.0% |
| 2011 Q4 | 8.86 Million INR | 78.79% |
| 2011 FY | 24.77 Million INR | -43.82% |
| 2010 FY | 44.1 Million INR | 4.64% |
| 2009 FY | 42.14 Million INR | 17.92% |
| 2008 Q4 | 13.57 Million INR | 0.0% |
| 2008 FY | 35.74 Million INR | 549.88% |
| 2007 FY | 5.5 Million INR | 0.0% |
| 2007 Q4 | 5.08 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott India Limited | 13.79 Billion INR | 96.982% |
| Cipla Limited | 105.7 Billion INR | 99.606% |
| Gland Pharma Limited | 9.9 Billion INR | 95.798% |
| GlaxoSmithKline Pharmaceuticals Limited | 13.6 Billion INR | 96.94% |
| Kopran Limited | 615.26 Million INR | 32.343% |
| Marksans Pharma Limited | 7.79 Billion INR | 94.657% |
| Pfizer Limited | 9.61 Billion INR | 95.669% |
| Sanofi India Limited | 7.79 Billion INR | 94.663% |
| SMS Pharmaceuticals Limited | 833.64 Million INR | 50.066% |